A Phase 4 interventional study of Brentuximab vedotin in Lymphoma, sponsored by Takeda. Completed at 40 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-19.
Sponsored by Takeda · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic — 1 open to participants now, 2 under way, none of them phase 3. Brentuximab Vedotin · Lymphoma, Large-Cell, Anaplastic.
Among the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic, this one is the 8th largest by enrollment, is the only one that started in 2014, is the only one in phase 4, and was the 12th registered.
397 studies on the registry are indexed under Lymphoma, Large-Cell, Anaplastic; 26 are open to participants now.
Browse Lymphoma, Large-Cell, Anaplastic studies →1 of the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic is open now, in 1 country. Recruiting first, the newest first:
New York Medical College · Sites in United States
Ages 1–39
By country, each count listing its studies:
Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 21 Lymphoma, Large-Cell, Anaplastic studies recruiting now, 12 (57%) set no upper age limit and 6 (29%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 1 · Phase 4 1
First in 2006; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is above the median of 37 across 306 interventional studies indexed under Lymphoma, Large-Cell, Anaplastic.
Median enrollment 44 across the 21 interventional studies. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 21 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 9 studies filed under Lymphoma, Large-Cell, Anaplastic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the antitumor efficacy of single-agent brentuximab vedotin 1.8 mg/kg administered intravenously (IV) every 3 weeks, as measured by the overall objective response rate (ORR) in patients with r/r sALCL following at least 1 multiagent chemotherapy regimen (cyclophosphamide, doxorubicin hydrochloride [hydroxydaunorubicin], vincristine sulfate [Oncovin], and prednisone [CHOP] or equivalent multiagent chemotherapy regimens with curative intent).
397 studies on the registry are indexed under Lymphoma, Large-Cell, Anaplastic; 26 are open to participants now.
This study's enrollment of 50 is above the median of 37 across 306 interventional studies indexed under Lymphoma, Large-Cell, Anaplastic.
Browse Lymphoma, Large-Cell, Anaplastic studies →Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Compared within Lymphoma, Large-Cell, Anaplastic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received brentuximab vedotin 1.8 mg/kg as a 30 minute intravenous (IV) infusion on Day 1 of each 3 week cycle. Participants with stable disease or better and without unacceptable toxicity were to receive a minimum of 8 cycles with the opportunity to receive a maximum of 16 cycles.
Drug: Brentuximab vedotin
Brentuximab vedotin IV infusion
Also known as: SGN-35, ADCETRIS
Objective Response Rate (ORR)
ORR was defined as the percentage of participants with a complete remission (CR) or partial remission (PR) by Independent Review Facility (IRF) response assessment according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.
Time frame: Up to data cut-off date: 04 May 2021 (Up to approximately 7 years)
Duration of Response (DOR) Per IRF
DOR was defined as the time between initial response and documented tumor progression in the subset of participants who achieved an objective response, either CR or PR. DOR per IRF was based upon the radiological assessment of measured lesions from an independent review facility. DOR was censored on the date of the last disease assessment documenting absence of progressive disease (PD) for participants who were lost to follow-up, withdrew consent, started a new anticancer therapy other than stem cell transplant (SCT), or discontinued treatment due to undocumented PD after the last adequate disease assessment.
Time frame: Until disease progression, death, or the data cut-off date: 4 May 2021 (Up to approximately 7 years)
Progression-free Survival (PFS) Per IRF
PFS is defined as the time from start of study treatment to first documentation of objective tumor progression or to death due to any cause, whichever comes first. PFS per IRF is based upon the radiological assessment from an independent review facility.
Time frame: Until disease progression, death, or the data cut-off date: 4 May 2021 (Up to approximately 7 years)
Complete Remission Rate (CRR) Per IRF
CRR is defined as percentage of participants with CR. CR is defined as the disappearance of all evidence of disease.
Time frame: Until disease progression, death, or the data cut-off date: 4 May 2021 (Up to approximately 7 years)
Overall Survival (OS)
OS is defined as the time from start of study treatment to date of death due to any cause.
Time frame: Until disease progression, death, or end of study (Up to approximately 10.7 years)
Percentage of Participants Receiving Hematopoietic Stem Cell Transplant (SCT) Following Treatment With Brentuximab Vedotin
Time frame: Until disease progression, death, or end of study (Up to approximately 10.7 years)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs by Severity (Grade 3 or Higher)
An adverse event (AE): any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to medicinal product. TEAE was defined as any AE that started after the first administration of study drug in this continuation study. Serious TEAEs: defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect, or is a medically important event.
Time frame: From first dose up to 30 days post last dose of study drug (Up to approximately 1 year)
Concentration of Serum Antibody-drug Conjugate (ADC) at the End of Infusion
Time frame: Cycle 1, Day 1 and Cycle 3, Day 1 at the end of infusion
Concentration of Serum Total Antibody (TAb) Conjugate Plus Free Total Antibody
Time frame: Cycle 1, Day 1 and Cycle 3, Day 1 at the end of infusion
Maximum Concentration for Unconjugated Drug- Monomethyl Auristatin E (MMAE)
Time frame: Cycle 1, Day 1 and Cycle 3, Day 1 at the end of infusion
Percentage of Participants With Presence of Anti-Therapeutic Antibodies (ATA) and Neutralizing Antibodies (NAb) to Brentuximab Vedotin
Time frame: Up to 16 cycles (each cycle = 21 days)
Participants took part in the study at various investigative sites globally from 23 January 2014 to 29 August 2024.
| Milestone | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Started | 50 |
| Completed | 19 |
| Not completed | 31 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Death | 25 |
| Withdrew: Withdrawal of informed consent | 1 |
| Withdrew: Reason not specified | 1 |
ORR was defined as the percentage of participants with a complete remission (CR) or partial remission (PR) by Independent Review Facility (IRF) response assessment according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.
| percentage of participants | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Objective Response Rate (ORR) | 64 (49 to 77) |
DOR was defined as the time between initial response and documented tumor progression in the subset of participants who achieved an objective response, either CR or PR. DOR per IRF was based upon the radiological assessment of measured lesions from an independent review facility. DOR was censored on the date of the last disease assessment documenting absence of progressive disease (PD) for participants who were lost to follow-up, withdrew consent, started a new anticancer therapy other than stem cell transplant (SCT), or discontinued treatment due to undocumented PD after the last adequate disease assessment.
| months | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Duration of Response (DOR) Per IRF | NA (19.71 to NA) |
PFS is defined as the time from start of study treatment to first documentation of objective tumor progression or to death due to any cause, whichever comes first. PFS per IRF is based upon the radiological assessment from an independent review facility.
| months | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Progression-free Survival (PFS) Per IRF | 20.9 (4.17 to NA) |
CRR is defined as percentage of participants with CR. CR is defined as the disappearance of all evidence of disease.
| percentage of participants | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Complete Remission Rate (CRR) Per IRF | 30 (18 to 45) |
OS is defined as the time from start of study treatment to date of death due to any cause.
| months | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Overall Survival (OS) | 67.6 (17.68 to NA) |
| percentage of participants | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Percentage of Participants Receiving Hematopoietic Stem Cell Transplant (SCT) Following Treatment With Brentuximab Vedotin | 28 |
An adverse event (AE): any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to medicinal product. TEAE was defined as any AE that started after the first administration of study drug in this continuation study. Serious TEAEs: defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect, or is a medically important event.
| percentage of participants | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| TEAEs | 94 |
| Serious TEAEs | 32 |
| Drug-Related TEAEs | 70 |
| TEAEs by Severity (Grade 3 or Higher) | 58 |
| micrograms per liter (µg/L) | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Cycle 1, Day 1 | 35 ± 35 |
| Cycle 3, Day 1 | 38 ± 25 |
| µg/L | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Cycle 1, Day 1 | 33 ± 29 |
| Cycle 3, Day 1 | 38 ± 23 |
| nanogram per milliliter (ng/ml) | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Cycle 1, Day 1 | 0.25 ± 87 |
| Cycle 3, Day 1 | 0.29 ± 88 |
| percentage of participants | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| ATA Positive | 30 |
| Neutralizing ATA Positive | 0.0 |
Collected over All-cause mortality: Throughout the study (Up to approximately 10.7 years); Serious and other adverse events: From first dose up to 30 days post last dose of study drug (up to approximately 1 year). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brentuximab Vedotin 1.8 mg/kg | 25/50 (50%) | 16/50 (32%) | 37/50 (74%) |
| Event | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Anaplastic large cell lymphoma T- and null-cell typesNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/50 |
| DiarrhoeaGastrointestinal disorders | 2/50 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/50 |
| General physical health deteriorationGeneral disorders | 2/50 |
| HypotensionVascular disorders | 2/50 |
| PneumoniaInfections and infestations | 2/50 |
| Abdominal incarcerated herniaGastrointestinal disorders | 1/50 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/50 |
| Aortic stenosisVascular disorders | 1/50 |
| Autonomic neuropathyNervous system disorders | 1/50 |
| Event | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Peripheral sensory neuropathyNervous system disorders | 9/50 |
| PyrexiaGeneral disorders | 9/50 |
| DiarrhoeaGastrointestinal disorders | 8/50 |
| NeutropeniaBlood and lymphatic system disorders | 8/50 |
| AnaemiaBlood and lymphatic system disorders | 7/50 |
| FatigueGeneral disorders | 6/50 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/50 |
| NauseaGastrointestinal disorders | 5/50 |
| Back painMusculoskeletal and connective tissue disorders | 4/50 |
| ConstipationGastrointestinal disorders | 4/50 |
Safety Population included all participants who received at least 1 dose of brentuximab vedotin.
| Age, Continuous(years) | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Mean | 56.4 ± 16.70 |
| Sex: Female, Male(Participants) | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Female | 31 |
| Male | 19 |
| Ethnicity (NIH/OMB)(Participants) | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 45 |
| Unknown or Not Reported | 3 |
| Race (NIH/OMB)(Participants) | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 50 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Belgium | 1 |
| Croatia | 2 |
| Czech Republic | 12 |
| Hungary | 5 |
| Poland | 8 |
| Portugal | 3 |
| Romania | 3 |
| Spain | 4 |
| Turkey | 6 |
| United Kingdom | 6 |
| Height(centimeters (cm)) | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Mean | 166.8 ± 10.40 |
| Weight(kilograms (kg)) | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Mean | 75.2 ± 20.73 |
| Body Mass Index (BMI)(kilograms per meter squared (kg/m^2)) | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Mean | 26.9 ± 6.39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2014 to primary completion in May 2021, 87 months.
Results were first posted in May 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin
Lymphoma, Large-Cell, Anaplastic →